Cargando…
Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-c...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Future Medicine Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793921/ https://www.ncbi.nlm.nih.gov/pubmed/35081732 http://dx.doi.org/10.2217/fon-2021-1248 |
| _version_ | 1784640718178877440 |
|---|---|
| author | Yasin, Ayse Irem Aydin, Sabin Göktas Sümbül, Bilge Koral, Lokman Şimşek, Melih Geredeli, Çağlayan Öztürk, Akın Perkin, Perihan Demirtaş, Derya Erdemoglu, Engin Hacıbekiroglu, İlhan Çakır, Emre Tanrıkulu, Eda Çoban, Ezgi Ozcelik, Melike Çelik, Sinemis Teker, Fatih Aksoy, Asude Fırat, Sedat T Tekin, Ömer Kalkan, Ziya Türken, Orhan Oven, Bala B Dane, Faysal Bilici, Ahmet Isıkdogan, Abdurrahman Seker, Mesut Türk, Hacı M Gümüş, Mahmut |
| author_facet | Yasin, Ayse Irem Aydin, Sabin Göktas Sümbül, Bilge Koral, Lokman Şimşek, Melih Geredeli, Çağlayan Öztürk, Akın Perkin, Perihan Demirtaş, Derya Erdemoglu, Engin Hacıbekiroglu, İlhan Çakır, Emre Tanrıkulu, Eda Çoban, Ezgi Ozcelik, Melike Çelik, Sinemis Teker, Fatih Aksoy, Asude Fırat, Sedat T Tekin, Ömer Kalkan, Ziya Türken, Orhan Oven, Bala B Dane, Faysal Bilici, Ahmet Isıkdogan, Abdurrahman Seker, Mesut Türk, Hacı M Gümüş, Mahmut |
| author_sort | Yasin, Ayse Irem |
| collection | PubMed |
| description | Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: NCT04771559 (ClinicalTrials.gov) |
| format | Online Article Text |
| id | pubmed-8793921 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Future Medicine Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87939212022-01-28 Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study Yasin, Ayse Irem Aydin, Sabin Göktas Sümbül, Bilge Koral, Lokman Şimşek, Melih Geredeli, Çağlayan Öztürk, Akın Perkin, Perihan Demirtaş, Derya Erdemoglu, Engin Hacıbekiroglu, İlhan Çakır, Emre Tanrıkulu, Eda Çoban, Ezgi Ozcelik, Melike Çelik, Sinemis Teker, Fatih Aksoy, Asude Fırat, Sedat T Tekin, Ömer Kalkan, Ziya Türken, Orhan Oven, Bala B Dane, Faysal Bilici, Ahmet Isıkdogan, Abdurrahman Seker, Mesut Türk, Hacı M Gümüş, Mahmut Future Oncol Research Article Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: NCT04771559 (ClinicalTrials.gov) Future Medicine Ltd 2022-01-27 2022-04 /pmc/articles/PMC8793921/ /pubmed/35081732 http://dx.doi.org/10.2217/fon-2021-1248 Text en © 2022 Future Medicine Ltd https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) |
| spellingShingle | Research Article Yasin, Ayse Irem Aydin, Sabin Göktas Sümbül, Bilge Koral, Lokman Şimşek, Melih Geredeli, Çağlayan Öztürk, Akın Perkin, Perihan Demirtaş, Derya Erdemoglu, Engin Hacıbekiroglu, İlhan Çakır, Emre Tanrıkulu, Eda Çoban, Ezgi Ozcelik, Melike Çelik, Sinemis Teker, Fatih Aksoy, Asude Fırat, Sedat T Tekin, Ömer Kalkan, Ziya Türken, Orhan Oven, Bala B Dane, Faysal Bilici, Ahmet Isıkdogan, Abdurrahman Seker, Mesut Türk, Hacı M Gümüş, Mahmut Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study |
| title | Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study |
| title_full | Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study |
| title_fullStr | Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study |
| title_full_unstemmed | Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study |
| title_short | Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study |
| title_sort | efficacy and safety profile of covid-19 vaccine in cancer patients: a prospective, multicenter cohort study |
| topic | Research Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793921/ https://www.ncbi.nlm.nih.gov/pubmed/35081732 http://dx.doi.org/10.2217/fon-2021-1248 |
| work_keys_str_mv | AT yasinayseirem efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT aydinsabingoktas efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT sumbulbilge efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT korallokman efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT simsekmelih efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT geredelicaglayan efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT ozturkakın efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT perkinperihan efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT demirtasderya efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT erdemogluengin efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT hacıbekirogluilhan efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT cakıremre efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT tanrıkulueda efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT cobanezgi efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT ozcelikmelike efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT celiksinemis efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT tekerfatih efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT aksoyasude efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT fıratsedatt efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT tekinomer efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT kalkanziya efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT turkenorhan efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT ovenbalab efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT danefaysal efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT biliciahmet efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT isıkdoganabdurrahman efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT sekermesut efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT turkhacım efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy AT gumusmahmut efficacyandsafetyprofileofcovid19vaccineincancerpatientsaprospectivemulticentercohortstudy |